Innovation Pharmaceuticals Granted Regulatory Approval to Start Phase 1 Trial of Oral Brilacidin in Ulcerative Colitis Program; Company Aims to Capture Large Market Opportunity for Novel Oral IBD Drug Candidates

NEXT STORY
Cooper University Health Care Announces Expansion of Extensive Military Training Programs with Partnership to Provide Specialized Medical Training to U.S. Military Personnel as Part of SMART Program
PREV STORY
Helsinn to present a scientific poster on acute care use following CINV prophylaxis with agents in breast cancer patients at the San Antonio Breast Cancer Symposium (SABCS) 2019
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Viterra Renews Partnership with STARS Air Ambulance

WINNIPEG, MANITOBA--(Marketwired - Sept. 11, 2017) - Viterra Inc. ("Viterra") is pleased to announce ...

author_avatar
NASDAQ Market News

DBV Technologies Announces Results from Phase II Study of Viaskin Milk in Milk-Allergic Patients

Press ReleaseMontrouge, France, February 26, 2018                                                                                                                                                                           DBV Technologies Announces Results from Phase ...

author_avatar
NASDAQ Market News

Veru Enrolls First Patient in International Phase 3 ARTEST Clinical Trial of Enobosarm in Metastatic Breast Cancer

author_avatar
NASDAQ Market News